sábado, 22 de abril de 2017

NIAID Funding News - April 19, 2017


April 19, 2017 NIAID Funding News

Feature Articles 

Where Are They Now? NIAID’s Apply for a Grant Webpages

In Part III of our series about popular relocated content, we cover the Apply for a Grant section—located within the “Grants & Contracts” tab of the top navigation bar.

Opportunities and Resources

Another Chance To Join the CFAR Program

NIH’s Centers for AIDS Research program supports research coordination, emerging research opportunities, and shared core facilities among institutions that receive significant HIV/AIDS funding from NIH.

Provide Manufacturing and Characterization Services for Vaccines and Other Biologics

A new request for proposals seeks services to develop multiple vaccines and biologic candidates that emerge from third-party sources.

Contractors: New RFP for Developing Interventional Agents for Infectious Diseases

NIAID anticipates awarding 10 multiple award indefinite quantity contracts and expects the performance period to begin summer of 2018.

Grantees: Act Quickly To Take Advantage of Cancer Immunotherapy Opportunity

For a limited time, administrative supplements are available to fund collaborative pilot projects seeking to reduce the incidence or severity of auto-inflammatory or autoimmune adverse events following cancer immunotherapy.

In The News

Guidance on Citing Interim Research Products in NIH Grant Applications

Investigators who want to accelerate dissemination and enhance the rigor of their work can now cite interim research products anywhere other research products are cited in a grant application or progress report.

Coming Soon: Opportunity To Add Regenerative Medicine Component to Ongoing Research

The 21st Century Cures Act provides funding to further the field of regenerative medicine using adult stem cells, including autologous cells.

News Briefs

Advice Corner

Understanding Indirect Costs

Having trouble distinguishing between direct and indirect costs for your federally funded research project? We’ve listed a few key points to help you better understand the difference.

Reader Questions

New Funding Opportunities

See other announcements at Opportunities & Announcements.
Send suggestions or comments to deaweb@niaid.nih.gov.

Show Me the Money! Finding Funding to Study the Clinical Effects of Mind and Body Interventions | NCCIH

Show Me the Money! Finding Funding to Study the Clinical Effects of Mind and Body Interventions | NCCIH

National Center for Complementary and Integrative Health (NCCIH)

wendy weber

Show Me the Money! Finding Funding to Study the Clinical Effects of Mind and Body Interventions

April 19, 2017
Wendy Weber, N.D., Ph.D., M.P.H.

At NCCIH, we are working hard to let the research community know about our new approach to funding research with human subjects that focuses on the clinical effects of complementary health approaches. We held a webinar yesterday to discuss why our Center will no longer accept most clinical trial applications through the Parent R01 and will, instead, encourage applicants to use a new series of funding opportunity announcements (FOAs) designed for investigator-initiated clinical trials (see NOT-AT-17-006). In this blog post, I’d like to share how our new FOAs provide pathways to support developmental steps for mind and body clinical trials.

Each of the clinical trial FOAs is targeted to a specific stage of clinical research. We want to help investigators select the appropriate FOA based on the amount of preliminary data that is available on the intervention’s effect in the patient population of interest. There are FOAs for early phase trials, intermediate trials, and full-scale efficacy, effectiveness, or pragmatic trials. The new series of FOAs will support investigators working to establish “building blocks” that bridge the gap from basic research to high-impact clinical trials on complementary and integrative health interventions.

Read the full blog post

New Drug Safety Communication on codeine and tramadol medicines- Drug Information Update

Drug Safety and Availability > FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women

FDA Logo, hands holding pills
The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.

The Food and Drug Administration (FDA) is restricting the use of codeine and tramadol medicines in children. Codeine is approved to treat pain and cough, and tramadol is approved to treat pain. These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children. These medicines should also be limited in some older children. Single-ingredient codeine and all tramadol-containing products are FDA-approved only for use in adults. We are also recommending against the use of codeine and tramadol medicines in breastfeeding mothers due to possible harm to their infants.
As a result, we are requiring several changes to the labels of all prescription medicines containing these drugs. These new actions further limit the use of these medicines beyond our 2013 restriction of codeine usein children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids. We are now adding:
  • FDA’s strongest warning, called a Contraindication, to the drug labels of codeine and tramadol alerting that codeine should not be used to treat pain or cough and tramadol should not be used to treat pain in children younger than 12 years.
  • A new Contraindication to the tramadol label warning against its use in children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids.
  • A new Warning to the drug labels of codeine and tramadol to recommend against their use in adolescents between 12 and 18 years who are obese or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.
  • A strengthened Warning to mothers that breastfeeding is not recommended when taking codeine or tramadol medicines due to the risk of serious adverse reactions in breastfed infants. These can include excess sleepiness, difficulty breastfeeding, or serious breathing problems that could result in death.
For more information please visit: Codeine and Tramadol

Emerging Resistance Genes in Shigella & Recommendations for Treating Infections

New CDC Health Advisory: Some Shigella infections may be harder to treat due to emerging resistance genes
Includes CDC recommendations for diagnosis and management of Shigella strains with possible reduced susceptibility to ciprofloxacin.
Shigella causes an estimated 500,000 cases of diarrhea in the U.S. each year.

Shigella causes an estimated 500,000 cases of diarrhea in the U.S. each year.

Due to emerging resistance genes, some Shigella infections may be harder to treat with ciprofloxacin, an antibiotic that’s often a first choice when treatment is needed.
Treating Shigella infections with ciprofloxacin when resistance genes are present raises two concerns:
  • The patient may have prolonged diarrhea or worsening of other symptoms, increased need for hospitalization, or a longer hospital stay.
  • If the patient isn’t treated appropriately they could be contagious longer and may be more likely to spread the infection to other people. 
Antimicrobial susceptibility tests (lab tests used to guide antibiotic choice) may not accurately predict whether Shigella infections with resistance genes can be treated effectively with ciprofloxacin.
If antibiotics are needed to treat a Shigella infection, it’s important to use one that will be effective. Using an antibiotic that isn’t effective can contribute to the growing problem of multidrug-resistant Shigella and increase the chance of others getting sick from this highly contagious germ. Read the full CDC Health Advisory for recommendations for clinicians, laboratories, and public health officials.
CDC is working with state and local public health departments and clinical partners to learn more about these new shigellosis cases and resistance genes.

FoodNet Report: Rapid Tests Challenge Ability to Track Illness Trends

Food Safety Masthead

FoodNet Report: Rapid Tests Challenge Ability to Track Illness Trends

Reducing foodborne illness depends in part on identifying which illnesses are decreasing and which are increasing. Yet recent changes in the use of tests that diagnose foodborne illness pose challenges to monitoring illnesses and progress toward preventing foodborne disease, according to a report published today in CDC’s Morbidity and Mortality Weekly Report.
Rapid diagnostic tests help doctors diagnose infections quicker than traditional culture methods, which require growing bacteria to determine what is causing illness. But without a bacterial culture, public health officials cannot get the detailed information needed to detect and prevent outbreaks, monitor disease trends, and identify antibiotic resistance.
Key Findings
The MMWR article includes the most recent data from CDC’s Foodborne Diseases Active Surveillance Network, or FoodNet, which collects data on 15% of the U.S. population. It summarizes preliminary 2016 data on nine germs spread commonly through food. In 2016, FoodNet reported 24,029 infections, 5,512 hospitalizations, and 98 deaths. This is the first time the numbers used for calculations of trends include bacterial infections diagnosed only by rapid diagnostic tests as well as those confirmed by traditional culture-based methods. Previously, these calculations used only those bacterial infections confirmed by culture-based methods. The most frequent causes of infection in 2016 were Salmonella and Campylobacter, which is consistent with previous years.
More Information

Infographic: 5 Steps to Clean Your Refrigerator


Follow these five tips for cleaning your refrigerator if you have a recalled food item there. Get a printable copy of the infographic on our Food Safety website.

Be Food Safe: Protect Yourself from Food Poisoning

Anybody can get food poisoning, but most people don’t think about food safety until they or someone they know gets sick after eating contaminated food. Read CDC’s feature to learn how to protect yourself and your loved ones from food poisoning.
Want to share this feature or other syndicated CDC content through your website or blog? Get them free, from CDC’s public health media library.

Free CE Webinar: Patient Perspectives on Dialysis Infections

Free Continuing Education Webinar:
Free Continuing Education Webinar:
Infections in Dialysis Centers: Understanding What Matters to Patients
Presentations will highlight perspectives on healthcare-associated infections (HAIs):
  • Patient perspectives on the prevention and management of infectious disease in hemodialysis centers
  • Approaches to engage dialysis patients in their care and in research
  • Strategies to engage hemodialysis patients in infection prevention: a patient’s perspective
Featured speakers include:
  • Allison Tong, MPH, MM, PhD; Associate Professor, Principal Research Fellow, Sydney School of Public Health, The University of Sydney-Australia
  • Mark Unruh, MD, MS; Professor and Chair, Department of Internal Medicine, Solomon, Gardner & Sterling Chair Section Chief, New Mexico VA Health System, Associate Director UNM Clinical and Translation Science Center, University of New Mexico School of Medicine
  • Ronald J. Krokey; Patient Advocate, Former Dialysis Patient
Don’t miss this FREE webinar with continuing education hosted by CDC’s Making Dialysis Safer for Patients Coalition.
  Join Us
 Webinar: Tune in to Safe Healthcare: Infections in Dialysis Centers: Understanding What Matters to Patients
 Date:  Tuesday, May 2, 2017
 Time: 3:00–4:00 p.m. EDT
 Sign up:  Pre-register (at no cost): https://cc.readytalk.com/r/ty1y33hzgvbl&eom
For more information about continuing education available for CDC’s Tune in to Safe Healthcare Webinar Series, visit: https://www.cdc.gov/hai/prevent/safe-healthcare-webinars.html.

BioEdge: Will Richard Branson erase the stigma of dyslexia? by Michael Cook | 22 Apr 2017 |

BioEdge: Will Richard Branson erase the stigma of dyslexia?

Will Richard Branson erase the stigma of dyslexia?

British billionaire entrepreneur Richard Branson is either a practical joker or a quirky eugenicist. On March 31 he announced the creation of the world’s first dyslexia-only sperm bank.

In the past, some sperm banks in the UK rejected dyslexic donors because they might be carriers of “common genetic diseases or malformations”. Ironically, they were reproached for being “eugenicist”. But Branson says on his personal blog that

“this is absurd when you think that some of the most successful people in the world are dyslexic. Rather than being seen as a weakness, dyslexia should be seen as a strength ... Dyslexia has been a massive help for me personally; it makes me think creatively and laterally, two major factors that helped me create Virgin and build a global brand ...Dyslexia is a different way of thinking, not a disadvantage and it shouldn’t stop young people from achieving success and striving to make their dreams a reality.”
The notion has the air of prank, but Branson says that he will launch “the world’s first dyslexic sperm bank” in London on May 2. A website already exists, MadeByDyslexia.org, which also promises great things on May 2.

As Stat noted, Branson’s holding company, the Virgin Group, has a habit of making announcements on April Fool’s Day, like left-handed telephones, a trip into an active volcano, and using trained ferrets to lay underground cables.

Watch this space. 


Saturday, April 22, 2017

We’re back from the Easter holidays, which in Australia are far longer than elsewhere, thank goodness. To get back into the rhythm of things, we have published two articles about “fake news” and bioethics. One reports that prospective IVF parents in Mississippi discovered to their horror that they were twins separated at birth. This went around the world before some spoilsport blew the whistle on it. The other is an announcement by British billionaire Richard Branson that he is setting up a sperm bank for dyslexics. Branson being Branson, it’s hard to tell whether this is fake news or not, but I suspect that it is.
The problem with BioEdge, some readers tell us, is that everything sounds like fake news. This, of course, is not true; we take great care to check our sources. However, all too often the articles seem to have been composed in some gigantic facility manned by bad news elves.
In fact, when you read today’s lead story, “Euthanised organ donors could dramatically shorten waitlists in Belgium, say doctors”, I must concede that it does sound so implausible as to be fake. But it’s not a report from The Onion, but from the Journal of the American Medical Association. Go figure. 

Michael Cook

by Michael Cook | Apr 22, 2017
There are some limitations, so the idea needs to be refined.
by Xavier Symons | Apr 22, 2017
Innovations in organ transplantation pose unique problems for bioethicists.
by Xavier Symons | Apr 22, 2017
Deaths by euthanasia increased 10% in the Netherlands in 2016, according to a new report.
by Xavier Symons | Apr 22, 2017
The Indian state of Assam may enact a strict 'two child policy' in response to concerns about rapid population growth in the region.
by Michael Cook | Apr 22, 2017
IVF parents discover that they are TWINS!!!!!!
by Michael Cook | Apr 22, 2017
He may have plans for a dyslexic sperm bank.
by Michael Cook | Apr 21, 2017
IVF industry angry at conservative approach
by Michael Cook | Apr 14, 2017
Released this week, "Change Agent" is a sci-fi thriller about genetic modification
Suite 12A, Level 2 | 5 George St | North Strathfield NSW 2137 | Australia
Phone: +61 2 8005 8605
Mobile: 0422-691-615
New Media Foundation | Level 2, 5 George St | North Strathfield NSW 2137 | AUSTRALIA | +61 2 8005 8605 

BioEdge: Will Richard Branson erase the stigma of dyslexia?